AAV-CRISPR-Cas13 eliminates human enterovirus and prevents death of infected miceResearch in context

Autor: Choong Tat Keng, Thinesshwary Yogarajah, Regina Ching Hua Lee, Irfan Bin Hajis Muhammad, Bing Shao Chia, Suraj Rajan Vasandani, Daryl Shern Lim, Ke Guo, Yi Hao Wong, Chee Keng Mok, Justin Jang Hann Chu, Wei Leong Chew
Jazyk: angličtina
Rok vydání: 2023
Předmět:
Zdroj: EBioMedicine, Vol 93, Iss , Pp 104682- (2023)
Druh dokumentu: article
ISSN: 2352-3964
DOI: 10.1016/j.ebiom.2023.104682
Popis: Summary: Background: RNA viruses account for many human diseases and pandemic events but are often not targetable by traditional therapeutics modalities. Here, we demonstrate that adeno-associated virus (AAV) -delivered CRISPR-Cas13 directly targets and eliminates the positive-strand EV-A71 RNA virus in cells and infected mice. Methods: We developed a Cas13gRNAtor bioinformatics pipeline to design CRISPR guide RNAs (gRNAs) that cleave conserved viral sequences across the virus phylogeny and developed an AAV-CRISPR-Cas13 therapeutics using in vitro viral plaque assay and in vivo EV-A71 lethally-infected mouse model. Findings: We show that treatment with a pool of AAV-CRISPR-Cas13-gRNAs designed using the bioinformatics pipeline effectively blocks viral replication and reduces viral titers in cells by >99.99%. We further demonstrate that AAV-CRISPR-Cas13-gRNAs prophylactically and therapeutically inhibited viral replication in infected mouse tissues and prevented death in a lethally challenged EV-A71-infected mouse model. Interpretation: Our results show that the bioinformatics pipeline designs efficient CRISPR-Cas13 gRNAs for direct viral RNA targeting to reduce viral loads. Additionally, this new antiviral AAV-CRISPR-Cas13 modality represents an effective direct-acting prophylactic and therapeutic agent against lethal RNA viral infections. Funding: Agency for Science, Technology and Research (A∗STAR) Assured Research Budget, A∗STAR Central Research Fund UIBR SC18/21-1089UI, A∗STAR Industrial Alignment Fund Pre-Positioning (IAF-PP) grant H17/01/a0/012, MOE Tier 2 2017 (MOE2017-T2-1-078; MOE-T2EP30221-0005), and NUHSRO/2020/050/RO5+5/NUHS-COVID/4.
Databáze: Directory of Open Access Journals